Brief Summary
Researchers are looking for new ways to treat people with endometrial cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs (EC) who have previously received treatment with platinum based therapy (a type of chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells) and immunotherapya treatment that uses a person's immune system to fight cancer. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.
Intervention / Treatment
- Biological: Sacituzumab tirumotecan
- Drug: Doxorubicin
- Drug: Paclitaxel
Inclusion Criteria
- Has a histologically-confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of endometrial carcinomacancer arising from tissues that line organs or carcinosarcoma.
- Has radiographically evaluable disease, either measurable or nonmeasurable per response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central review (BICR).
- Has received prior platinum-based chemotherapy and anti-programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination.